PURPOSE: Little is known about the dynamic changes of matrix metalloproteinases (MMPs) and their inhibitors (TIMPs) in sepsis. Our aim was therefore to investigate the time course of MMPs and their inhibitors in patients experiencing severe sepsis. METHODS: Our prospective controlled analysis included 38 patients with severe sepsis. Plasma levels of MMP-2, MMP-9, TIMP-1, and TIMP-2 were measured daily at a 5-day-long period with enzyme-linked immunosorbent assay. Seventeen healthy volunteers were invited as controls. RESULTS: MMP-2 showed no difference compared to controls, whereas significantly elevated MMP-9 levels were detected on admission (P < .005). Significantly elevated but declining TIMP-1 levels were measured during the whole trial (P < .002-.004). Except for the second day, TIMP-2 levels were significantly lower than controls (P < .05-.009). MMP2/TIMP-1 ratios were significantly lower in septic patients (P < .03-.006), whereas MMP-2/TIMP-2 ratios were elevated throughout our study (P < .03-.006). MMP-9/TIMP-1 ratios were significantly lower at the first 3 days (P < .05-.008). MMP-9/TIMP-2 was significantly elevated on admission (P < .006). CONCLUSIONS: Our research is the first follow-up study dealing with MMPs, TIMPs, and their ratios in severe sepsis. Our results indicate that MMPs and TIMPs may play a crucial role in severe sepsis, especially TIMP-1, MMP-9, and possibly TIMP-2, after an extensive study.
PURPOSE: Little is known about the dynamic changes of matrix metalloproteinases (MMPs) and their inhibitors (TIMPs) in sepsis. Our aim was therefore to investigate the time course of MMPs and their inhibitors in patients experiencing severe sepsis. METHODS: Our prospective controlled analysis included 38 patients with severe sepsis. Plasma levels of MMP-2, MMP-9, TIMP-1, and TIMP-2 were measured daily at a 5-day-long period with enzyme-linked immunosorbent assay. Seventeen healthy volunteers were invited as controls. RESULTS:MMP-2 showed no difference compared to controls, whereas significantly elevated MMP-9 levels were detected on admission (P < .005). Significantly elevated but declining TIMP-1 levels were measured during the whole trial (P < .002-.004). Except for the second day, TIMP-2 levels were significantly lower than controls (P < .05-.009). MMP2/TIMP-1 ratios were significantly lower in septicpatients (P < .03-.006), whereas MMP-2/TIMP-2 ratios were elevated throughout our study (P < .03-.006). MMP-9/TIMP-1 ratios were significantly lower at the first 3 days (P < .05-.008). MMP-9/TIMP-2 was significantly elevated on admission (P < .006). CONCLUSIONS: Our research is the first follow-up study dealing with MMPs, TIMPs, and their ratios in severe sepsis. Our results indicate that MMPs and TIMPs may play a crucial role in severe sepsis, especially TIMP-1, MMP-9, and possibly TIMP-2, after an extensive study.
Authors: Mashael F Alqahtani; Craig M Smith; Scott L Weiss; Susan Dawson; Hantamalala Ralay Ranaivo; Mark S Wainwright Journal: PLoS One Date: 2016-04-18 Impact factor: 3.240
Authors: Markus Huber-Lang; Kristina N Ekdahl; Rebecca Wiegner; Karin Fromell; Bo Nilsson Journal: Semin Immunopathol Date: 2017-09-12 Impact factor: 9.623
Authors: Cesar A Ugarte-Gil; Paul Elkington; Robert H Gilman; Jorge Coronel; Liku B Tezera; Antonio Bernabe-Ortiz; Eduardo Gotuzzo; Jon S Friedland; David A J Moore Journal: PLoS One Date: 2013-04-22 Impact factor: 3.240
Authors: Guadalupe Martin; Víctor Asensi; A Hugo Montes; Julio Collazos; Victoria Alvarez; José A Carton; Francisco Taboada; Eulalia Valle-Garay Journal: Sci Rep Date: 2014-05-16 Impact factor: 4.379
Authors: Bálint Nagy; Gábor Woth; Ákos Mérei; Lilla Nagy; János Lantos; Gábor Menyhei; Lajos Bogár; Diána Mühl Journal: Indian J Med Res Date: 2016-02 Impact factor: 2.375